NattoPharma announces the publication of a groundbreaking new study on its proprietary MenaQ7® brand of natural vitamin K2 standardized to MK-7 content. The company initiated the three-year clinical intervention study on the effects of MenaQ7 on bone health and it is now available online in the leading journal Osteoporosis International as an online first article.
The MenaQ7 supplementation group significantly increased the circulating active Osteocalcin (cOC), a well-established biomarker for bone and vitamin K status. The inactive protein, ucOC, in the MenaQ7 group, decreased with 51% +/- 21 % as compared to the placebo group (+4 % +/- 49%). This is pointing to the positive MenaQ7 bone effect. After three years of supplementation, improvements in both bone mineral content (BMC) and bone mineral density (BMD) were statistically significant in the MenaQ7 group. Moreover, bone strength (BS) was statistically improved, demonstrating therapeutic benefits for the MenaQ7 group as compared to the placebo group.
“These demonstrated improvements in clinical outcomes are extremely important”, says Dr. Cees Vermeer, principal investigator for the study at VitaK laboratory at Maastricht University. “We have documented that MenaQ7 supplementation over three years supports bone health in postmenopausal women, confirming that bone health benefits of vitamin K2 are best demonstrated over longer periods than previously thought.”
Hogne Vik, CEO of NattoPharma, comments, “The results from the three-year human study on MenaQ7 show for the first time that daily intake of 180 micrograms MenaQ7 may help postmenopausal women protect their bones.”
Frode M. Bohan, chairman of the NattoPharma Board, promises, “NattoPharma will actively use the findings together with our customers and partners to improve our commercial platform, commercializing MenaQ in the supplement and functional food markets throughout the world”.